Lucid Diagnostics

Lucid Diagnostics Gross Margin

The Gross Margin of Lucid Diagnostics (LUCD) as of Nov 5, 2026 is -60.26 %. In the previous year, Gross Margin was -90.20 % — a change of -33.19% (higher).

Gross Margin

-60.26 %

YoY

-33.19%

Last updated:

Gross Margin of Lucid Diagnostics is 2025 -60.26 % . Gross Margin of Lucid Diagnostics was 2024 -90.20 % . It decreases by -33.19% higher compared to the previous year.

Lucid Diagnostics's gross margin stands at -60.3%, down from -17.0% several years earlier.

The Lucid Diagnostics Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2021
-17.00 USD
Jan 1, 2022
-858.62 USD
Jan 1, 2023
-249.18 USD
Jan 1, 2024
-90.20 USD
Jan 1, 2025
-60.26 USD
The Lucid Diagnostics Gross Margin history
YEARGross MarginYoY
-60.26 %-33.19%
-90.20 %-63.80%
-249.18 %-70.98%
-858.62 %+4,950.71%
-17.00 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Lucid Diagnostics Stock analysis

What does Lucid Diagnostics do? Lucid Diagnostics, Inc. generates revenue through its commercial-stage medical diagnostics technology focused on patients with gastroesophageal reflux disease (GERD). The company markets EsoGuard, a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells, and EsoCheck, a noninvasive swallowable balloon capsule catheter device used to sample these cells in office procedures. These products address the progression from chronic heartburn to esophageal precancer and lethal esophageal adenocarcinoma (EAC). The EsoCheck device consists of a vitamin pill-sized rigid plastic capsule tethered to a thin silicone catheter, featuring a soft silicone balloon with textured ridges that swab surface esophageal cells. This sampling capability enables the subsequent application of the EsoGuard assay. The company also develops EsoCure, an esophageal ablation device intended to treat dysplastic BE before it progresses to EAC, thereby expanding its therapeutic offerings within the segment of patients suffering from reflux-related conditions. Lucid Diagnostics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Lucid Diagnostics stock

Gross Margin of Lucid Diagnostics is -60.26 % in 2025.

Gross Margin of Lucid Diagnostics changed from -90.20 % to -60.26 %, representing a -33.19% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Lucid Diagnostics since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Lucid Diagnostics with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Lucid Diagnostics

All Key Metrics — Lucid Diagnostics